Europe - FRA:1AE - NL0010832176 - Common Stock
The current stock price of 1AE.DE is 695 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 22.02 | 355.96B | ||
1ABBV.MI | ABBVIE INC | 21.97 | 355.08B | ||
AMG.DE | AMGEN INC | 13.58 | 137.77B | ||
GIS.DE | GILEAD SCIENCES INC | 15.17 | 125.94B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 24.14 | 90.61B | ||
ARGX.BR | ARGENX SE | 93.39 | 42.69B | ||
1INSM.MI | INSMED INC | N/A | 29.80B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 21.76B | ||
IDP.DE | BIOGEN INC | 9.18 | 18.63B | ||
1EXAS.MI | EXACT SCIENCES CORP | N/A | 9.34B | ||
0QF.DE | MODERNA INC | N/A | 9.26B | ||
1MRNA.MI | MODERNA INC | N/A | 9.25B |
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
ARGENX SE
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND NL
Employees: 1599
Phone: 31763030
The current stock price of 1AE.DE is 695 EUR. The price increased by 1.22% in the last trading session.
The exchange symbol of ARGENX SE is 1AE and it is listed on the Deutsche Boerse Ag exchange.
1AE.DE stock is listed on the Deutsche Boerse Ag exchange.
25 analysts have analysed 1AE.DE and the average price target is 736.04 EUR. This implies a price increase of 5.9% is expected in the next year compared to the current price of 695. Check the ARGENX SE stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ARGENX SE (1AE.DE) has a market capitalization of 42.53B EUR. This makes 1AE.DE a Large Cap stock.
ARGENX SE (1AE.DE) currently has 1599 employees.
The Revenue of ARGENX SE (1AE.DE) is expected to grow by 85.31% in the next year. Check the estimates tab for more information on the 1AE.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
1AE.DE does not pay a dividend.
ARGENX SE (1AE.DE) will report earnings on 2025-10-30, before the market open.
The PE ratio for ARGENX SE (1AE.DE) is 93.04. This is based on the reported non-GAAP earnings per share of 7.47 and the current share price of 695 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 1AE.DE.
ChartMill assigns a technical rating of 3 / 10 to 1AE.DE.
ChartMill assigns a fundamental rating of 5 / 10 to 1AE.DE. 1AE.DE has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months 1AE.DE reported a non-GAAP Earnings per Share(EPS) of 7.47. The EPS increased by 345.45% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 41.97% | ||
ROA | 17.84% | ||
ROE | 21% | ||
Debt/Equity | 0.01 |
25 analysts have analysed 1AE.DE and the average price target is 736.04 EUR. This implies a price increase of 5.9% is expected in the next year compared to the current price of 695.
For the next year, analysts expect an EPS growth of 805.38% and a revenue growth 85.31% for 1AE.DE